BR112016002462A8 - Métodos para melhorar os sintomas da asma usando benralizumabe - Google Patents

Métodos para melhorar os sintomas da asma usando benralizumabe

Info

Publication number
BR112016002462A8
BR112016002462A8 BR112016002462A BR112016002462A BR112016002462A8 BR 112016002462 A8 BR112016002462 A8 BR 112016002462A8 BR 112016002462 A BR112016002462 A BR 112016002462A BR 112016002462 A BR112016002462 A BR 112016002462A BR 112016002462 A8 BR112016002462 A8 BR 112016002462A8
Authority
BR
Brazil
Prior art keywords
benralizumab
asthma symptoms
methods
improve asthma
improve
Prior art date
Application number
BR112016002462A
Other languages
English (en)
Other versions
BR112016002462A2 (pt
Inventor
Ward Christine
Roskos Lorin
Wang Bing
Raible Donald
Original Assignee
Medimmune Llc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Astrazeneca Ab filed Critical Medimmune Llc
Publication of BR112016002462A2 publication Critical patent/BR112016002462A2/pt
Publication of BR112016002462A8 publication Critical patent/BR112016002462A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE BENRALIZUMABE OU DE UM SEU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO PARA MELHORAR OS SINTOMAS DA ASMA E BENRALIZUMABE OU UM SEU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO PARA USO PARA MELHORAR OS SINTOMAS DA ASMA. Neste documento são conferidos métodos para melhorar os sintomas da asma, por exemplo, conforme medido por um questionário de controle de asma, compreendendo a administração ao paciente de uma quantidade eficaz de benralizumabe ou de um seu fragmento de ligação ao antígeno.
BR112016002462A 2013-08-12 2014-08-07 Métodos para melhorar os sintomas da asma usando benralizumabe BR112016002462A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864950P 2013-08-12 2013-08-12
PCT/US2014/050122 WO2015023508A2 (en) 2013-08-12 2014-08-07 Methods for improving asthma symptoms using benralizumab

Publications (2)

Publication Number Publication Date
BR112016002462A2 BR112016002462A2 (pt) 2017-09-12
BR112016002462A8 true BR112016002462A8 (pt) 2018-06-12

Family

ID=52448839

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002462A BR112016002462A8 (pt) 2013-08-12 2014-08-07 Métodos para melhorar os sintomas da asma usando benralizumabe

Country Status (18)

Country Link
US (1) US9441047B2 (pt)
EP (3) EP3033103B1 (pt)
JP (2) JP6803229B2 (pt)
KR (1) KR102337601B1 (pt)
CN (2) CN105451761A (pt)
AU (3) AU2014306960B2 (pt)
BR (1) BR112016002462A8 (pt)
CA (1) CA2918050C (pt)
DK (2) DK3536339T3 (pt)
ES (2) ES2740355T3 (pt)
HK (2) HK1221647A1 (pt)
HU (2) HUE045402T2 (pt)
MX (1) MX368474B (pt)
PL (2) PL3536339T3 (pt)
RU (2) RU2020123894A (pt)
SG (1) SG11201600484TA (pt)
TR (1) TR201910413T4 (pt)
WO (1) WO2015023508A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2676333C2 (ru) * 2013-08-12 2018-12-28 Астразенека Аб Способы снижения частоты приступов астмы с применением бенрализумаба
SG11201600483QA (en) * 2013-08-12 2016-02-26 Medimmune Llc Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP2016534996A (ja) * 2013-10-15 2016-11-10 メディミューン，エルエルシー ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2018538249A (ja) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2205007C (en) 1995-09-11 2010-12-14 Masamichi Koike Antibody against human interleukin-5 receptor .alpha. chain
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1688437A4 (en) 2003-10-08 2007-09-26 Kyowa Hakko Kogyo Kk SPECIALLY BINDING ANTIBODY COMPOSITION TO IL-5 RECEPTOR
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
EP2068927B1 (en) * 2007-05-14 2015-10-21 MedImmune, LLC Methods of reducing eosinophil levels
KR101615474B1 (ko) * 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
WO2013066780A2 (en) 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
SG11201600483QA (en) * 2013-08-12 2016-02-26 Medimmune Llc Methods for increasing forced expiratory volume in asthmatics using benralizumab
RU2676333C2 (ru) * 2013-08-12 2018-12-28 Астразенека Аб Способы снижения частоты приступов астмы с применением бенрализумаба

Also Published As

Publication number Publication date
KR102337601B1 (ko) 2021-12-10
DK3536339T3 (da) 2021-12-20
AU2020202564A1 (en) 2020-05-07
HK1221647A1 (zh) 2017-06-09
RU2020123894A (ru) 2020-09-18
ES2901634T3 (es) 2022-03-23
HUE057065T2 (hu) 2022-04-28
MX2016001195A (es) 2016-07-21
JP2016527326A (ja) 2016-09-08
CN105451761A (zh) 2016-03-30
EP3536339A1 (en) 2019-09-11
SG11201600484TA (en) 2016-02-26
WO2015023508A2 (en) 2015-02-19
EP3988114A1 (en) 2022-04-27
ES2740355T3 (es) 2020-02-05
BR112016002462A2 (pt) 2017-09-12
US9441047B2 (en) 2016-09-13
AU2014306960A1 (en) 2016-02-04
US20150044204A1 (en) 2015-02-12
KR20160042123A (ko) 2016-04-18
RU2016108734A3 (pt) 2018-06-18
CN111617244A (zh) 2020-09-04
EP3033103A2 (en) 2016-06-22
CA2918050C (en) 2023-10-03
WO2015023508A8 (en) 2015-10-15
RU2016108734A (ru) 2017-09-19
TR201910413T4 (tr) 2019-08-21
HK1225303A1 (zh) 2017-09-08
EP3536339B1 (en) 2021-10-06
AU2014306960B2 (en) 2020-01-16
PL3033103T3 (pl) 2019-10-31
PL3536339T3 (pl) 2022-02-21
RU2728578C2 (ru) 2020-07-30
JP6803229B2 (ja) 2020-12-23
AU2023214323A1 (en) 2023-10-19
DK3033103T3 (da) 2019-08-05
EP3033103B1 (en) 2019-06-05
EP3033103A4 (en) 2017-03-22
HUE045402T2 (hu) 2019-12-30
MX368474B (es) 2019-10-04
WO2015023508A3 (en) 2015-04-16
JP2020100653A (ja) 2020-07-02
CA2918050A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
CO2017011851A2 (es) Compuestos novedosos
BR112018007017A2 (pt) polipeptídeos
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112016002462A8 (pt) Métodos para melhorar os sintomas da asma usando benralizumabe
BR112014018475A8 (pt) Compostos de imidazopirrolidinona, suas formas cristalinas e seu uso, e composição farmacêutica
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112017027132A2 (pt) reguladores do nrf2
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
BR112016013493A2 (pt) molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
EA201591839A1 (ru) Терапевтические пептиды
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112017005202A2 (pt) anticorpos anti-met e composições
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112016004324A2 (pt) anticorpos
BR112015018504A2 (pt) moduladores de flap
BR112016023554A2 (pt) novos compostos macrocíclicos
BR112014018767A8 (pt) Compostos de pirroldicarboxamidas fundidas e composição farmacêutica que os compreende
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
BR112016017046A2 (pt) Anticorpos contra glicoproteína f de vírus hendra e nipah

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.